Navigation Links
Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin)
Date:6/2/2009

href="http://www.advancedlifesciences.com" target="_new">www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 866.713.8567 (domestic) or 617.597.5326 (international). The passcode for the conference call is 15573457. A replay of the conference call will be available until July 10, 2009. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 27483036. Investors are advised to dial into the call at least ten minutes prior to the call to register.

About Restanza

Restanza is a novel, once-a-day, oral antibiotic that is under review for approval by the FDA for the treatment of CAP. It has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections, and, again in in vitro tests, it appears to be effective against penicillin-, macrolide-, and fluoroquinolone-resistant bacteria. Restanza's demonstrated potency and ability to overcome bacterial resistance may be due to its mechanism of action resulting in specificity for its bacterial target. In addition to its utility in CAP, Restanza is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, but the drug is not yet approved for this or any other indication.

About Community Acquired Pneumonia (CAP)

CAP is the sixth most common cause of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. CAP affects 5.6 million patients in the United States each year, with 10 million physician visits and 2 million hospitalizations occurring annually.

Macr
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R)
2. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
5. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
7. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
8. Induction Chemotherapy Followed by ChemoRadiotherapy Increased Time-to-Treatment Failure Compared to ChemoRadiotherapy Alone in Patients With Unresectable Locally Advanced Head & Neck Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. New Preliminary Data from Two Studies Show Clinical Activity of Neratinib in Combination with Trastuzumab and in Combination with Paclitaxel in Advanced HER-2 Positive Breast Cancer
11. Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013 /PRNewswire-iReach/ -- Today at American Society for ... Ginocchio discussed Specific Technologies blood culture ... of microorganisms producing bloodstream infection. Dr. Ginocchio is ... Division of Infectious Disease Diagnostics at North Shore-LIJ ... health system. (Photo: http://photos.prnewswire.com/prnh/20130520/CG16829 ) ...
(Date:5/20/2013)... Calif. , May 20, 2013 /PRNewswire-iReach/ -- ... of the first study demonstrating detection of pathogenic ... Yersinia pestis and Bacillus anthracis ... and Prevention,s list of potential bio-threats. This seminal ... and Technology Laboratory, Salisbury ...
(Date:5/20/2013)... , May 20, 2013  Hill-Rom Holdings, Inc. (NYSE: ... a management presentation at the 38 th Annual ... on May 30, 2013, at 1:30 p.m. ... You are invited to listen to the live ... or access it directly at http://www.media-server.com/m/p/f7bj3q84 . A ...
Breaking Medicine Technology:Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 2Specific Technologies Bloodstream Infection Identification Solutions Discussed at the American Society for Microbiology Conference by Award Lecturer Christine Ginocchio 3Specific Technologies Detects and Identifies Potential Bioterrorism Pathogenic Bacteria 2
... 7, 2011 Rochester Medical Corporation (NASDAQ: ... the previously announced purchase of Laprolan B.V., the former ... BioSciences N.V. Under the terms of the purchase agreement ...  For more information regarding this transaction please refer to ...
... April 7, 2011 Ascension Orthopedics, Inc., a world ... the TITAN Modular Total Shoulder.  The surgeries were performed ... Baltimore, MD.     "I have been ... of years in my practice. Now that Ascension has ...
Cached Medicine Technology:Ascension Orthopedics Announces TITAN™ Modular Shoulder Implantations at Union Memorial Hospital 2
(Date:5/20/2013)... DC (PRWEB) May 20, 2013 Medicare ... are overwhelmingly satisfied, citing lower costs, convenient access to ... from Hart Research Associates released today by the Pharmaceutical ... D seniors (9.5 million) are currently enrolled in plans ... pharmacy choices, and overall value of plans with preferred ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 A new ... by MedEx Direct, the creators of the MedEx Pack ... the Benefits of Pharmacy Home Delivery, in order to provide ... their prescriptions are handled. Clyde Furuta, MedEx Direct owner ... home delivery is that with a product like the MedEx ...
(Date:5/20/2013)... improved health care and significant reductions in drug costs ... between physicians and drug company representatives who promote the ... This system, which has been in place for decades, ... to date on new medications, and always provided generous ... the newest drugs, as well as other supplies and ...
(Date:5/20/2013)... T.E.N. announced today that it would ... Security Executive® Northeast Awards now through Friday, July ... Security Executive® of the Year and ISE® People’s ... a positive impact on their organizations through risk ... security; and the ISE® Project of the Year, ...
(Date:5/20/2013)... Geneva, Switzerland (PRWEB) May 20, 2013 ... discovery for lead identification and cell line development for ... that the Company’s co-founder will present data on the ... Development & Engineering Conference, May 20 - 23 ... La Jolla, California. Selexis’ co-founder and scientific advisory board ...
Breaking Medicine News(10 mins):Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Health News:Benefits of Pharmacy Home Delivery Report Published by MedEx Direct 2Health News:Breakup of physician, drug company relationship could improve health care, cut cost 2Health News:Breakup of physician, drug company relationship could improve health care, cut cost 3Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 2Health News:T.E.N. Announces Call for Nominations for the ISE® Northeast Awards 2013 3Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 2Health News:Selexis SA to Present Technology Platform Data at Cell Line Development & Engineering 3
... Children, WASHINGTON, Oct. 3 Campaign for ... veto of the,Children,s Health Insurance Program Reauthorization bill ... nation,s broken health care systems. The bill,the president ... for 6.6 million children and provide coverage to ...
... Information,Systems, Inc., (Nasdaq: MEDW ) announced that ... the company regarding the company,s,non-compliance with Nadsaq Marketplace ... company,s audit committee. This issue arose,due to the ... an audit,committee member. On October 2, 2007, ...
... say , WEDNESDAY, Oct. 3 (HealthDay News) -- Identifying ... the best chemotherapy for patients, U.S. research suggests. , ... most likely to respond to standard first-line therapy and ... a second-line therapy, based on gene expression profiling," lead ...
... outcomes for high-risk patients , , WEDNESDAY, Oct. 3 (HealthDay ... the bare-metal kind for high-risk patients with blocked coronary ... of restenosis -- having the artery become blocked again ... following two years for those getting drug-coated stents, 7.4 ...
... Oct. 3 Abaxis, Inc.,(Nasdaq: ABAX ), ... systems, announced today the launch of the Kidney,Check ... Piccolo xpress(TM) point of,care analyzer. The new ... and,radiology centers in the United States to determine ...
... Nowhere are the,consequences of premature birth more evident than ... the next week, 563 babies,will be born too soon ... watch their babies be admitted into a NICU. Having ... the most frightening and overwhelming,experiences a parent faces. ...
Cached Medicine News:Health News:Mediware Information Systems, Inc. Receives Notice from the Nasdaq Stock Market 2Health News:Gene Tests Match Up Lung Tumors, Best Treatment 2Health News:Study Finds Benefits With Drug-Coated Stents 2Health News:Study Finds Benefits With Drug-Coated Stents 3Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 2Health News:Abaxis Announces New Waived Kidney Check Panel Exclusively for Imaging and Radiology Centers 3Health News:March of Dimes NICU Family Support(R) Programs Give Florida Families Comfort and Information During a Crisis 2
... The innovative E.coli ... Pro-Lab offers definitive identification ... the use of a ... the possibility of cross-reactions ...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
The Oxoid Legionella Latex Test is a latex agglutination test for the identification of predominant Legionella species grown on plate media from patients with suspected Legionellosis or from environm...
Inquire...
Medicine Products: